Objective: We aimed to compare the efficacy of isosorbide mononitrate and doxazosin in the treatment of lower urinary tract symptoms (LUTS). Patients and Methods: 80 patients with LUTS were included in this randomized clinical study. All patients were evaluated with uroflowmetry, post-void residual (PVR) urine, prostate volume, International Prostate Symptom Score (IPSS), serum PSA, urinalysis and culture. 40 patients were prescribed doxazosin for 4 weeks, another 40 were prescribed isosorbide mononitrate for 4 weeks. Urologic re-evaluation was done at the end of the study. Results: 74 patients completed the study. The mean age of patients was 59.6 ± 0.7 years, the mean PSA value was 1.7 ± 0.1 ng/ml and the mean prostate volume was 41.9 ± 1.7 ml. Doxazosin markedly improved IPSS (from 16.2 ± 0.7 to 9.5 ± 0.5), maximum urinary flow rate (from 10.9 ± 0.7 to 12.8 ± 0.6 ml/s) and PVR urine (from 68.1 ± 9.4 to 39.0 ± 4.4 ml) (p < 0.0001, p < 0.0001, p = 0.0004, respectively). Isosorbide only improved IPSS (from 16.5 ± 0.9 to 14.6 ± 0.8) (p = 0.032). Conclusions: Daily administration of isosorbide does not seem to be an alternative to α-blocker therapy. Controlled, randomized novel studies are required to establish that whether nitric oxide donors are an effective alternative in LUTS treatment.

Keywords:
Lower urinary tract symptoms, Benign prostatic hyperplasia, Nitric oxide, Isosorbide, Doxazosin, Uroflowmetry, International Prostate Symptom Score
1.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, N'Dow J, Nordling J, de la Rosette JJ: EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms, including benign prostatic obstruction. Eur Urol 2013;64:118-140.
2.
Mamas MA, Reynard RM, Brading AF: Nitric oxide and the lower urinary tract: current concepts, future prospects. Urology 2003;61:1079-1085.
3.
Hedlund P: Nitric oxide/cGMP-mediated effects in the outflow region of the lower urinary tract - is there a basis for pharmacological targeting of cGMP? World J Urol 2005;23:362-367.
4.
Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H, Chang TS: Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995;45:435-439.
5.
Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K: Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997;33:1-8.
6.
Waldkirch ES, Uckert S, Langnäse K, Richter K, Jonas U, Wolf G, Andersson KE, Stief CG, Hedlund P: Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol 2007;52:495-501.
7.
Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H: Effects of nitric oxide on human and canine prostates. Urology 1995;45:440-446.
8.
Kedia G, Uckert S, Scheller F, Chigogidze T, Managadze L, Jonas U, Truss MC: In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 2006;67:1292-1297.
9.
Kedia GT, Uckert S, Jonas U, Kuczyk MA, Burchardt M: The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008;26:603-609.
10.
Reitz A, Müntener M, Haferkamp A, Hohenfellner M, Schurch B: Targeting bladder outlet obstruction from benign prostatic enlargement via the nitric oxide/cGMP pathway? BJU Int 2005;96:250-253.
11.
Takeda M, Araki I, Mochizuki T, Nakagomi H, Kobayashi H, Sawada N, Zakohji H: The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: pathophysiology of voiding dysfunction and pharmacological therapy. J Pharmacol Sci 2010;112:121-127.
12.
Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L: Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-1113.
13.
Oelke M, Guiliano F, Mirone V, Xu L, Cox D, Viktrup L: Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-925.
14.
Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M: A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
15.
Reitz A, Bretscher S, Knapp PA, Knapp PA, Wefer B, Schurch B: The effect of nitric oxide on the resting tone and the contractile behaviour of the external urethral sphincter: a functional urodynamic study in healthy humans. Eur Urol 2004;45:367-373.
16.
Muntener M, Schurch B, Wefer B, Reitz A: Systemic nitric oxide augmentation leads to a rapid decrease of the bladder outlet resistance in healthy men. Eur Urol 2006;50:112-118.
17.
Reitz A, Knapp PA, Muntener M, Schurch B: Oral nitric oxide donors: a new pharmacological approach to detrusor-sphincter dyssynergia in spinal cord injured patients? Eur Urol 2004;45:516-520.
18.
Klotz T, Mathers MJ, Bloch W, Nayal W, Engelmann U: Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol 1999;31:335-341.
19.
Roshani A, Khosropanah I, Salehi M, Kamran AN: Effects of isosorbide dinitrate on the urinary flow rate in patients with benign prostatic hyperplasia. Urol J 2010;7:183-187.
20.
Andersson KE, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L: Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn 2011;30:292-301.
21.
Müntener M, Reitz A, Wefer B, Schurch B: Systemic augmentation of nitric oxide: is there an immediate effect on the urinary flow rate in healthy men? Urol Int 2006;76:31-35.
22.
Tadayyon F, Izadpanahi M, Aali S, Mazdak H, Khorrami MH: The effect of sublingual isosorbide dinitrate on acute urinary retention due to benign prostatic hyperplasia. Saudi J Kidney Dis Transpl 2012;23:782-785.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.